Virpax Pharmaceuticals VRPX

$ 0.69 -5.08%

Quarterly report 2024-Q2
added 08-12-2024

Virpax Pharmaceuticals Financial Statements 2011-2024 | VRPX

Annual Financial Statements Virpax Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	4.54 M	1.02 M	14.2 M	-	-	-	-	-	-	-	-	-	-
Shares	1.17 M	1.17 M	6.68 M	-	-	-	-	-	-	-	-	-	-
Historical Prices	3.88	0.87	2.13	-	-	-	-	-	-	-	-	-	-
Net Income	-15.2 M	-21.7 M	-12.1 M	-4.34 M	-3.31 M	-2.64 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-15.7 M	-21.8 M	-12 M	-4.2 M	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	92.8 K	148 K	-	-	-	-	-	-	-	-	-
EBITDA	-15.7 M	-21.8 M	-12 M	-	-3.18 M	-2.63 M	-	-	-	-	-	-	-
Operating Expenses	15.7 M	21.8 M	12 M	4.2 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	10.6 M	11.1 M	915 K	2.9 M	2.56 M	1.48 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Virpax Pharmaceuticals

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	1.98 M	1.17 M	1.17 M	11.7 M	1.17 M	1.17 M	11.7 M	11.7 M	11.7 M	11.7 M	11.7 M	6.01 M	4.96 M	3.95 M	3.15 M	3.14 M	3.09 M	3.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.45 M	-3.22 M	-	-5.99 M	-3.11 M	-1.52 M	-	-7.64 M	-5.88 M	-5.14 M	-	-3.22 M	-2.34 M	-2.38 M	-	-1.71 M	-1.27 M	-656 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-3.46 M	-3.3 M	-	-6.12 M	-3.24 M	-1.65 M	-	-7.72 M	-5.9 M	-5.12 M	-	-3.25 M	-2.31 M	-2.35 M	-	-1.66 M	-1.23 M	-616 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	28.9 K	34 K	30.7 K	-	45.7 K	43.3 K	40.6 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-3.46 M	-3.3 M	-	-6.12 M	-3.24 M	-1.65 M	-	-7.72 M	-5.9 M	-5.12 M	-	-3.25 M	-2.31 M	-2.35 M	-	-1.66 M	-1.23 M	-616 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	3.46 M	3.3 M	-	6.12 M	3.24 M	1.65 M	-	7.72 M	5.9 M	5.12 M	-	3.25 M	2.31 M	2.35 M	-	1.66 M	1.23 M	616 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	1.5 M	1.69 M	-	4.62 M	1.95 M	415 K	-	4.91 M	208 K	175 K	-	122 K	303 K	370 K	-	435 K	572 K	449 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency